Literature DB >> 18160007

Brain magnetic resonance imaging white matter lesions are frequent in HTLV-I carriers and do not discriminate from HAM/TSP.

Daniel J Morgan1, Marina F Caskey, Cristiane Abbehusen, Jamary Oliveira-Filho, Cesar Araujo, Aurelia F Porto, Silvane Braga Santos, Gloria O Orge, Maria Jose Joia, Andre L Muniz, Isadora Siqueira, Marshall J Glesby, Edgar Carvalho.   

Abstract

Human T lymphotropic virus (HTLV)-I is known to cause HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP) and other pronounced disease in less than 4% of those infected. However, evidence is accumulating that a proportion of HTLV-I carriers have neurological and urological symptoms without fulfilling criteria for HAM/TSP. Brain white matter (WM) lesions on magnetic resonance imaging (MRI) are frequently seen in HAM/TSP. HTLV-I carriers with MRI scans for other neurological diagnoses have WM lesions more frequently than expected. We studied 10 patients with HAM/TSP and 20 HTLV-I carriers without overt neurological disease and evaluated clinical characteristics, viral load, total, small, large, confluent WM lesion number, and lesion volume on MRI. Cerebral WM lesions were found in of 85% of HTLV-I carriers and 80% of HAM/TSP patients. Lesion number, size or location was no different between carriers and HAM/TSP. Cognitive function was lower in HAM/TSP (p = 0.045) but did not correlate with WM lesion number. Viral load and peripheral blood mononuclear cell interferon production correlated positively (p = 0.001) but did not correlate with lesion number or volume. Conventional brain MRI frequently shows WM lesions in HTLV-I-infected individuals suggesting potential early central nervous system inflammation with rare development of progressive disease.

Entities:  

Mesh:

Year:  2007        PMID: 18160007      PMCID: PMC2593463          DOI: 10.1089/aid.2007.0077

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  28 in total

1.  Analysis of HTLV-I proviral load in 202 HAM/TSP patients and 243 asymptomatic HTLV-I carriers: high proviral load strongly predisposes to HAM/TSP.

Authors:  M Nagai; K Usuku; W Matsumoto; D Kodama; N Takenouchi; T Moritoyo; S Hashiguchi; M Ichinose; C R Bangham; S Izumo; M Osame
Journal:  J Neurovirol       Date:  1998-12       Impact factor: 2.643

2.  Assessment of MRI criteria for MS in Japanese MS and HAM/TSP.

Authors:  Y Kuroda; M Matsui; M Yukitake; K Kurohara; H Takashima; Y Takashima; C Endo; A Kato; F Mihara
Journal:  Neurology       Date:  1995-01       Impact factor: 9.910

3.  Quantitative assessment of subclinical spasticity in human T-cell lymphotropic virus type I infection.

Authors:  J R Zunt; J O Alarcón; S Montano; W T Longstreth; R Price; K K Holmes
Journal:  Neurology       Date:  1999-07-22       Impact factor: 9.910

4.  [Magnetic resonance in HTL-I associated myelopathy. Leukoencephalopathy and spinal cord atrophy].

Authors:  A C Ferraz; A A Gabbai; N Abdala; R G Nogueira
Journal:  Arq Neuropsiquiatr       Date:  1997-12       Impact factor: 1.420

5.  A method to improve interrater reliability of visual inspection of brain MRI scans in dementia.

Authors:  J Victoroff; W J Mack; S T Grafton; S S Schreiber; H C Chui
Journal:  Neurology       Date:  1994-12       Impact factor: 9.910

6.  [HTLV-1 associated myelopathies in the city of Salvador, Bahia].

Authors:  A Melo; I Gomes; K Mattos
Journal:  Arq Neuropsiquiatr       Date:  1994-09       Impact factor: 1.420

7.  Characterization of cerebral white matter lesions of HTLV-I-associated myelopathy/tropical spastic paraparesis in comparison with multiple sclerosis and collagen-vasculitis: a semiquantitative MRI study.

Authors:  A J Godoy; J Kira; K Hasuo; I Goto
Journal:  J Neurol Sci       Date:  1995-11       Impact factor: 3.181

8.  Leukoencephalopathy in HTLV-I-associated myelopathy/tropical spastic paraparesis: MRI analysis and a two year follow-up study after corticosteroid therapy.

Authors:  J Kira; K Fujihara; Y Itoyama; I Goto; K Hasuo
Journal:  J Neurol Sci       Date:  1991-11       Impact factor: 3.181

Review 9.  An HTLV-I vaccine: why, how, for whom?

Authors:  G de Thé; R Bomford
Journal:  AIDS Res Hum Retroviruses       Date:  1993-05       Impact factor: 2.205

Review 10.  Chronic myelopathy associated with human T-lymphotropic virus type I (HTLV-I).

Authors:  A Gessain; O Gout
Journal:  Ann Intern Med       Date:  1992-12-01       Impact factor: 25.391

View more
  20 in total

1.  Human T-lymphotropic virus type I or II (HTLV-I/II) associated with recurrent longitudinally extensive transverse myelitis (LETM): two case reports.

Authors:  Silvia R Delgado; William A Sheremata; Andrew D Brown; Micheline McCarthy
Journal:  J Neurovirol       Date:  2010-05       Impact factor: 2.643

2.  HTLV-I-associated myelopathy/tropical spastic paraparesis: semiautomatic quantification of spinal cord atrophy from 3-dimensional MR images.

Authors:  Iordanis E Evangelou; Raya Massoud; Steven Jacobson
Journal:  J Neuroimaging       Date:  2012-02-03       Impact factor: 2.486

3.  Effects of Physiotherapy in the Treatment of Neurogenic Bladder in Patients Infected With Human T-Lymphotropic Virus 1.

Authors:  Rosana C P Andrade; José A Neto; Luciana Andrade; Tatiane S Oliveira; Dislene N Santos; Cassius J V Oliveira; Márcio J Prado; Edgar M Carvalho
Journal:  Urology       Date:  2015-12-24       Impact factor: 2.649

Review 4.  Epidemiology, treatment, and prevention of human T-cell leukemia virus type 1-associated diseases.

Authors:  Denise Utsch Gonçalves; Fernando Augusto Proietti; João Gabriel Ramos Ribas; Marcelo Grossi Araújo; Sônia Regina Pinheiro; Antônio Carlos Guedes; Anna Bárbara F Carneiro-Proietti
Journal:  Clin Microbiol Rev       Date:  2010-07       Impact factor: 26.132

5.  Helminthic infection and the risk of neurologic disease progression in HTLV-1.

Authors:  Michael A Sundberg; Davi Costa; Gloria Orge; Néviton M Castro; André Muniz; Marshall J Glesby; Edgar M Carvalho
Journal:  J Clin Virol       Date:  2012-01-10       Impact factor: 3.168

6.  Clinical manifestations in individuals with recent diagnosis of HTLV type I infection.

Authors:  Shelene K W Poetker; Aurelia F Porto; Silvana P Giozza; Andre L Muniz; Marina F Caskey; Edgar M Carvalho; Marshall J Glesby
Journal:  J Clin Virol       Date:  2011-03-08       Impact factor: 3.168

7.  Hypometabolism of watershed areas of the brain in HTLV-1-associated myelopathy/tropical spastic paraparesis.

Authors:  Akitoshi Taniguchi; Hitoshi Mochizuki; Shigeki Nagamachi; Yuka Ebihara; Nobuyuki Ishii; Kazutaka Shiomi; Masamitsu Nakazato
Journal:  Neurol Sci       Date:  2015-07-09       Impact factor: 3.307

8.  Neurologic abnormalities in HTLV-I- and HTLV-II-infected individuals without overt myelopathy.

Authors:  H H Biswas; J W Engstrom; Z Kaidarova; G Garratty; J W Gibble; B H Newman; J W Smith; A Ziman; J L Fridey; R A Sacher; E L Murphy
Journal:  Neurology       Date:  2009-09-08       Impact factor: 9.910

9.  HTLV-1-associated myelopathy in a solid organ transplant recipient.

Authors:  Maria Jose Montesdeoca Andrade; Edgar Patricio Correa Diaz; Maria Eugenia Buestán
Journal:  BMJ Case Rep       Date:  2016-06-06

10.  Case Report: Cognitive Impairment without Clinical Spinal Disease May Be the First Sign of HTLV-1 Neurological Alteration.

Authors:  Aline Rejane Rosa de Castro; Ludimila Labanca; Luciana Macedo de Resende; Denise Utsch-Gonçalves
Journal:  Am J Trop Med Hyg       Date:  2020-02       Impact factor: 2.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.